Dr Reddys Laboratories Ltd Share Price

Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg

NSE: DRREDDY Large Cap ISIN: INE089A01031

As on 22 January 2025 at 13:19 IST

₹1,295.80

+ 7.65

(0.59%)

Sell Buy

About Dr Reddys Laboratories Ltd

Dr. Reddy’s Laboratories Ltd is a global pharmaceutical company that aims to make medicines more approachable. Founded in 1984 by Dr. Kallam Anji Reddy, the company has its headquarters in Hyderabad, Telangana, India. Dr. Reddy’s is known for producing medicines that target a range of therapeutic areas. The company is committed to making high-quality medicines. They develop, manufacture, and sell a variety of pharmaceutical products. These include active pharmaceutical ingredients (APIs), generics, biosimilars, and over-the-counter (OTC) products. Their medicines can treat issues related to cardiovascular health, diabetes, oncology, and dermatology. Read More...

Over 1 Month

-3.97%

Over 6 Months

-4.88%

Over 1 Year

13.51%

Over 3 Years

43.25%

Dr Reddys Laboratories Ltd Summary

Close ₹ 1,295.80

Open ₹ 1,291

High ₹ 1,308

Low ₹ 1,288

Volume 8,10,242

Net Turnover (in ₹) ₹ 95,85,35,182.15

52Wk High ₹ 1,421.49

52Wk Low ₹ 1,120

52Wk High / Low

1,120

1,421.49

Dr Reddys Laboratories Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 1,07,486.32

EPS (TTM) 57.64

Book Value (BV) 322.47

Div. Yield 0.62 %

P/E (TTM) 22.35

Price/Book Value 4

Delivery % 49.42 %

Face Value 1

Key Ratios

PE Ratio 23.65

PB Ratio 4.22

EV to Sales 5.25

PEG Ratio 0.36

ROA 17.27

ROE 19.42

Debt-Equity 0.02

Net Profit Margin 22.29

Operating Profit Margin 34.84

Dr Reddys Laboratories Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	28,905.40	25,725.20	22,029.60	19,338.90	18,137.60
Total Expenses	21,719.10	19,713.70	19,038.50	16,503.40	16,308
Profit Before Tax	7,201	6,048.50	3,061.40	2,883.50	1,885.70
Profit After Tax	5,577.90	4,507.30	2,182.50	1,951.60	2,026
Operating Profit after Depreciation	7,357.40	6,154.30	3,086.90	2,932.50	1,927.90

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	10,493.90	9,274	8,135.30	8,816.90	7,949
Total Non Current Assets	14,058.50	11,859.60	11,964.60	12,066.50	10,626.20
Total Current Assets	24,805.30	20,425.50	17,782.30	14,550.30	12,599.10
TOTAL ASSETS	38,863.80	32,285.10	29,746.90	26,616.80	23,225.30
Total Shareholder's Fund	28,254.80	23,286.10	19,212.40	17,641.70	15,598.80

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	4,543.30	5,887.50	2,810.80	3,570.30	2,984.10
Net Cash used in Investing Activities	-4,034.20	-4,108.70	-2,565.40	-2,254.70	-494.80
Net Cash used in Financing Activities	-376.30	-2,686.10	-242.20	-29.80	-2,515.90

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	20,346.10	17,553.80	14,887.20	14,150.20	12,593.60
Total Expenses	14,554.80	13,687.80	12,663.40	11,094	9,817.80
Profit Before Tax	5,791.30	3,866	2,223.80	3,056.20	2,775.80
Profit After Tax	4,342	2,612.80	1,623.20	2,186.40	2,937.70
Operating Profit after Depreciation	5,813.10	3,882.90	2,261.80	3,102.90	2,823.60

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	7,628.20	7,220.60	6,164.40	5,868	4,461.60
Total Non Current Assets	12,543.40	11,586.50	11,004.30	10,685.40	9,369.10
Total Current Assets	17,815.90	13,788.30	13,491.30	10,944.20	10,106.70
TOTAL ASSETS	30,359.30	25,374.80	24,495.60	21,629.60	19,475.80
Total Shareholder's Fund	24,240.80	20,474.20	18,336.20	16,983.70	15,191.90

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	3,449.70	5,052.90	1,338.70	3,514.20	1,839.20
Net Cash used in Investing Activities	-3,428.70	-3,403.20	-1,990.10	-1,453.60	-1,689.20
Net Cash used in Financing Activities	68.10	-2,696.90	505.50	-794.30	-224.10

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	8,038.20	7,696.10	7,113.80	7,236.80	6,902.60
Total Expenses	5,961.70	5,566.20	5,282.60	5,213.70	4,894.30
Profit Before Tax	1,917.40	1,882.60	1,605.20	1,829.10	1,916.70
Profit After Tax	1,341.90	1,392.40	1,309.80	1,380.90	1,482.20
Operating Profit after Depreciation	2,390.10	2,323	2,032.20	2,242	2,327.50

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	6,696.30	5,841.20	5,104.80	4,103	4,838.70
Total Expenses	3,974.70	3,888.20	3,726.20	3,446.70	3,209.60
Profit Before Tax	2,640.80	1,913.90	1,339.20	631.90	1,600.60
Profit After Tax	1,882.10	1,417.20	1,034.80	475.20	1,192.60
Operating Profit after Depreciation	2,929.20	2,170.80	1,591.30	883.90	1,852.20

Dr Reddys Laboratories Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 1,278.22

S2 1,268.28

S3 1,250.92

Pivot 1,295.58

R1 1,305.52

R2 1,322.88

R3 1,332.82

Moving Average

20 SMA 1,348.44

50 SMA 1,285.79

100 SMA 1,305.83

200 SMA 1,286.37

Dr Reddys Laboratories Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

Dr Reddys Laboratories Ltd

₹40/Share

Announcement Date 16 Jul 2024

Record Date 17 Jul 2024

Div Yield 800%

Dr Reddys Laboratories Ltd Peer Comparison

Company	Price	Market Cap (in ₹ Cr)
Dr Reddys Laboratories Ltd	₹1,288.45	₹1,07,511.36
Sun Pharmaceuticals Industries Ltd	₹1,761.80	₹4,22,714.84
Divis Laboratories Ltd	₹5,818.40	₹1,54,460.24
Cipla Ltd	₹1,427.30	₹1,15,270.75
Torrent Pharmaceuticals Ltd	₹3,157.60	₹1,06,862.73
Mankind Pharma Ltd	₹2,563.35	₹1,05,755.34

Dr Reddys Laboratories Ltd News

Dr Reddys Laboratories receives affirmation in credit ratings for bank facilities

27 Dec 2024, 06:12 pm

Dr Reddys Laboratories Ltd soars 2.41%, Gains for third straight session

Dr Reddys Laboratories Ltd is quoting at Rs 1387.8, up 2.41% on the day as on 12:49 IST on the NSE. The stock is up 18.44% in last one year as compared to a 9.51% gain in NIFTY and a 36.31% gain in the Nifty Pharma index.

27 Dec 2024, 01:05 pm

DRL arm incorporates new WOS to expand operations in Finland

Dr Reddy's Laboratories announced that its wholly-owned subsidiary Dr Reddy's Laboratories SA, Switzerland, (DRSA) has incorporated a new wholly-owned subsidiary (WOS) in Finland, named 'Dr Reddy's Finland Oy'.

24 Dec 2024, 11:16 am

Dr Reddys Laboratories to convene board meeting

On 23 January 2025

24 Dec 2024, 10:51 am

Dr Reddys Laboratories Ltd gains for third straight session

Dr Reddys Laboratories Ltd is quoting at Rs 1356.8, up 2.35% on the day as on 12:49 IST on the NSE. The stock is up 22.14% in last one year as compared to a 11.83% jump in NIFTY and a 39.64% jump in the Nifty Pharma index.

20 Dec 2024, 01:05 pm

Dr Reddys Laboratories Ltd Stock Analysis

Annual revenue for Dr Reddys Laboratories Ltd increased by 15.91% to ₹20,346.10 crore in FY 2024 from ₹17,553.80 crore in FY 2023.
Annual Net Profit for Dr Reddys Laboratories Ltd increased by 66.18% to ₹4,342 crore in FY 2024 from ₹2,612.80 crore in FY 2023.
Promoter Shareholding in Dr Reddys Laboratories Ltd decreased by 0.03% in the most recent quarter, from 26.65% in June 2024 to 26.64% in September 2024.
Dr Reddys Laboratories Ltd delivered a 1-year return of 13.51% compared to the Nifty 50, which provided a return of 8.41% as of the last trading session.
Dr Reddys Laboratories Ltd share price moved up by 0.59% from its previous close of INR ₹1,288.15. The latest Dr Reddys Laboratories Ltd share price is INR ₹1,295.80.
Dr Reddys Laboratories Ltd share price today has been at a low of 1,288 and a high of 1,308. Over the past 52 weeks, the Dr Reddys Laboratories Ltd share price has seen a low of 1,120 and a high of 1,421.49.

About Dr Reddys Laboratories Ltd

Dr. Reddy’s Laboratories Ltd is a global pharmaceutical company that aims to make medicines more approachable. Founded in 1984 by Dr. Kallam Anji Reddy, the company has grown significantly over the last 40 years. Headquartered in Hyderabad, Telangana, India, Dr. Reddy’s operates worldwide. They develop, manufacture, and sell a variety of pharmaceutical products. These include active pharmaceutical ingredients (APIs), generics, biosimilars, and over-the-counter (OTC) products.

Dr. Reddy’s is known for producing medicines that target a range of therapeutic areas. Their medicines can treat issues related to cardiovascular health, diabetes, oncology, and dermatology. Among its most recognised products is Omes (omeprazole). It is a medication for gastrointestinal issues.

Although Dr. Reddy’s is not the largest pharmaceutical company, it is highly regarded for its innovative approach. The company continues to grow its influence within the industry by focusing on quality and affordability.
The promoters hold approximately 26.65 % of the company’s shares. This reflects its strong commitment to its growth and future direction. Here is a list of its top managing promoters - ‘

K Satish Reddy
G V Prasad
Claudio Albrecht

The company’s registered office is located at Banjara Hills in Hyderabad, Telangana. Its registrars and transfer agents are situated in Hyderabad as well. Dr. Reddy’s has built a solid reputation for its mission of providing access to affordable and innovative medicines. The company’s vision and mission reflect this focus and guide everything it does.

The objective of Dr. Reddy’s Laboratories Ltd

Dr. Reddy’s Laboratories has a clear vision and mission that guides its actions and decisions. These principles show its commitment to improving global health by enabling access to good medicines.

The vision of Dr. Reddy’s is to become a leading global pharmaceutical company. Their aim is to provide affordable and innovative medicines for healthier lives. This vision highlights the company’s dedication to addressing unmet medical needs and improving the quality of life for patients all over the world. Dr. Reddy’s does not just focus on expanding its business but aims to make a real impact by ensuring that advanced healthcare solutions reach those who need them most.
Dr. Reddy’s wants to bridge the gap between high-quality healthcare solutions and the people who require them. The company strives to meet this vision by offering medicines that are effective, accessible, and affordable.

The company’s mission is clear: to give access to affordable and effective medicines because "good health can’t wait." This simple yet powerful mission statement shows that Dr. Reddy’s knows how crucial it is for patients to get access to good medications. The company places a strong emphasis on improving health outcomes. It is this mission that drives every part of its business—from research and development to marketing and sales.

Innovation lies at the heart of Dr. Reddy’s Laboratories. The company invests heavily in research and development (R&D) to discover new therapies and improve existing ones. It uses cutting-edge technology to stay ahead of the latest scientific advancements. Dr. Reddy’s creates medicines that not only work but are also more accessible to a wider audience.

Making healthcare affordable is a core aspect of Dr. Reddy’s mission. The company is committed to making high-quality medicines available at prices that people can afford. One way Dr. Reddy’s does this is by offering a broad portfolio of generic medicines. These medicines provide cost-effective alternatives to expensive brand-name drugs.

Generics play a crucial role in healthcare systems worldwide by reducing the financial burden on patients. They do this while maintaining the same level of efficacy as their branded counterparts. Through these lower-cost alternatives, Dr. Reddy’s helps make high-quality healthcare more accessible for millions of people across the globe.

Dr. Reddy’s Laboratories is not just focused on India but operates globally. It makes its presence felt in key markets like the United States, Europe and emerging markets across Africa and Latin America. This global reach allows the company to provide much-needed medicines to patients all over the world.

One of the ways Dr. Reddy’s ensures its products are available globally is through partnerships with other organisations. These partnerships help the company tap into new markets and ensure that its medicines are available to people from all walks of life.
At the heart of Dr. Reddy’s strategy is a focus on the patient. The company places a strong emphasis on understanding and addressing the needs of its customers. Whether that means improving product quality, speeding up time to market, or providing better service. This patient-centric approach ensures that Dr. Reddy’s delivers solutions that make a difference in the patient’s lives.

Dr. Reddy’s Laboratories Ltd is much more than just a pharmaceutical company. It is a pioneer in making healthcare affordable and accessible to millions of people across the globe. Through its clear vision and mission, the company is driving positive change in the world of healthcare by focusing on innovation, affordability, and sustainability. Through its unwavering focus on making "good health accessible", Dr. Reddy’s Laboratories is truly living up to its mission every day.